Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ENZY's Cash to Debt is ranked higher than
75% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. ENZY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ENZY' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.92
ENZY's Equity to Asset is ranked higher than
89% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ENZY: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
ENZY' s Equity to Asset Range Over the Past 10 Years
Min: 0.67  Med: 0.92 Max: 0.93
Current: 0.92
0.67
0.93
Interest Coverage No Debt
ENZY's Interest Coverage is ranked higher than
65% of the 464 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ENZY' s Interest Coverage Range Over the Past 10 Years
Min: 8.09  Med: 19.76 Max: No Debt
Current: No Debt
F-Score: 6
Z-Score: 9.36
M-Score: -2.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 8.24
ENZY's Operating margin (%) is ranked higher than
76% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. ENZY: 8.24 )
Ranked among companies with meaningful Operating margin (%) only.
ENZY' s Operating margin (%) Range Over the Past 10 Years
Min: -1.51  Med: 14.76 Max: 18.1
Current: 8.24
-1.51
18.1
Net-margin (%) 8.37
ENZY's Net-margin (%) is ranked higher than
79% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. ENZY: 8.37 )
Ranked among companies with meaningful Net-margin (%) only.
ENZY' s Net-margin (%) Range Over the Past 10 Years
Min: -3.75  Med: 14.64 Max: 17.54
Current: 8.37
-3.75
17.54
ROE (%) 3.14
ENZY's ROE (%) is ranked higher than
78% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. ENZY: 3.14 )
Ranked among companies with meaningful ROE (%) only.
ENZY' s ROE (%) Range Over the Past 10 Years
Min: -3.14  Med: 4.78 Max: 6.52
Current: 3.14
-3.14
6.52
ROA (%) 2.89
ENZY's ROA (%) is ranked higher than
81% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. ENZY: 2.89 )
Ranked among companies with meaningful ROA (%) only.
ENZY' s ROA (%) Range Over the Past 10 Years
Min: -1.89  Med: 7.81 Max: 12.16
Current: 2.89
-1.89
12.16
ROC (Joel Greenblatt) (%) 8.31
ENZY's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. ENZY: 8.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ENZY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -0.51  Med: 14.41 Max: 28.12
Current: 8.31
-0.51
28.12
» ENZY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ENZY Guru Trades in Q3 2015

Julian Robertson 804,854 sh (New)
Jim Simons 146,000 sh (+76.98%)
John Paulson 4,238,275 sh (unchged)
» More
Q4 2015

ENZY Guru Trades in Q4 2015

Jim Simons 217,700 sh (+49.11%)
Julian Robertson 1,162,845 sh (+44.48%)
John Paulson 4,238,275 sh (unchged)
» More
Q1 2016

ENZY Guru Trades in Q1 2016

John Paulson 4,224,139 sh (-0.33%)
Julian Robertson 1,143,145 sh (-1.69%)
Jim Simons 181,000 sh (-16.86%)
» More
Q2 2016

ENZY Guru Trades in Q2 2016

Jim Simons 241,000 sh (+33.15%)
John Paulson 4,224,139 sh (unchged)
Julian Robertson 577,407 sh (-49.49%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMEX:PFNX, NYSE:EVGN, NAS:ITEK, NAS:GLYC, OTCPK:MXDHF, NAS:VTVT, NAS:CDXS, NAS:VTL, NAS:NYMX, NAS:RGLS, NAS:MDWD, AMEX:PIP, OTCPK:CLVLF, NAS:CRBP, NAS:RDHL, NAS:EGLT, OTCPK:SPHRY, OTCPK:CTIX, NAS:KMDA, NAS:ATHX » details
Traded in other countries:EZ4.Germany,
Enzymotec Ltd develops, manufactures, markets & sells innovative bio-functional lipid ingredients, and final products, based on sophisticated proprietary processes & technologies. The Company's segments include Nutrition Segment & VAYA Pharma Segment.

Top Ranked Articles about Enzymotec Ltd

Julian Robertson Sells Half of Stake in John Paulson-Backed Company Hedge fund pioneer was fourth largest shareholder of 'medical foods' company
Roughly a year after starting to invest in the company, Julian Robertson (Trades, Portfolio) has chopped half his stake in Enzymotec Ltd. (NASDAQ:ENZY), a maker of nutritional ingredients and medical foods. Read more...
Tiger Management Founder Julian Robertson Ups Stake in Enzymotec Biotech company is up 25% for the year
Guru Julian Robertson (Trades, Portfolio) is a legendary billionaire investor and founder of Tiger Management, which netted an outstanding average return of 32% from 1980 to 2000. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 41.21
ENZY's P/E(ttm) is ranked lower than
60% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 28.72 vs. ENZY: 41.21 )
Ranked among companies with meaningful P/E(ttm) only.
ENZY' s P/E(ttm) Range Over the Past 10 Years
Min: 14.53  Med: 31.03 Max: 63.09
Current: 41.21
14.53
63.09
PE(NRI) 41.21
ENZY's PE(NRI) is ranked lower than
60% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ENZY: 41.21 )
Ranked among companies with meaningful PE(NRI) only.
ENZY' s PE(NRI) Range Over the Past 10 Years
Min: 14.53  Med: 31.03 Max: 63.09
Current: 41.21
14.53
63.09
P/B 1.31
ENZY's P/B is ranked higher than
87% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. ENZY: 1.31 )
Ranked among companies with meaningful P/B only.
ENZY' s P/B Range Over the Past 10 Years
Min: 1  Med: 1.55 Max: 11.01
Current: 1.31
1
11.01
P/S 3.51
ENZY's P/S is ranked higher than
78% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. ENZY: 3.51 )
Ranked among companies with meaningful P/S only.
ENZY' s P/S Range Over the Past 10 Years
Min: 1.26  Med: 3.61 Max: 5.88
Current: 3.51
1.26
5.88
PFCF 30.83
ENZY's PFCF is ranked lower than
54% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 27.82 vs. ENZY: 30.83 )
Ranked among companies with meaningful PFCF only.
ENZY' s PFCF Range Over the Past 10 Years
Min: 21.46  Med: 35.28 Max: 451.3
Current: 30.83
21.46
451.3
POCF 22.44
ENZY's POCF is ranked higher than
51% of the 187 Companies
in the Global Biotechnology industry.

( Industry Median: 22.41 vs. ENZY: 22.44 )
Ranked among companies with meaningful POCF only.
ENZY' s POCF Range Over the Past 10 Years
Min: 10.93  Med: 22.06 Max: 686.67
Current: 22.44
10.93
686.67
EV-to-EBIT 27.02
ENZY's EV-to-EBIT is ranked lower than
55% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 23.40 vs. ENZY: 27.02 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.2  Med: 23.1 Max: 51.4
Current: 27.02
7.2
51.4
EV-to-EBITDA 17.70
ENZY's EV-to-EBITDA is ranked higher than
55% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 20.40 vs. ENZY: 17.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.3  Med: 18 Max: 34.9
Current: 17.7
6.3
34.9
Current Ratio 7.64
ENZY's Current Ratio is ranked higher than
70% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. ENZY: 7.64 )
Ranked among companies with meaningful Current Ratio only.
ENZY' s Current Ratio Range Over the Past 10 Years
Min: 2.31  Med: 7.42 Max: 8.76
Current: 7.64
2.31
8.76
Quick Ratio 5.35
ENZY's Quick Ratio is ranked higher than
57% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ENZY: 5.35 )
Ranked among companies with meaningful Quick Ratio only.
ENZY' s Quick Ratio Range Over the Past 10 Years
Min: 1.5  Med: 5.46 Max: 7.31
Current: 5.35
1.5
7.31
Days Inventory 459.60
ENZY's Days Inventory is ranked lower than
93% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.14 vs. ENZY: 459.60 )
Ranked among companies with meaningful Days Inventory only.
ENZY' s Days Inventory Range Over the Past 10 Years
Min: 121.07  Med: 156.74 Max: 459.6
Current: 459.6
121.07
459.6
Days Sales Outstanding 92.53
ENZY's Days Sales Outstanding is ranked lower than
69% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. ENZY: 92.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 92.53  Med: 111.4 Max: 128.19
Current: 92.53
92.53
128.19
Days Payable 135.50
ENZY's Days Payable is ranked higher than
76% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.75 vs. ENZY: 135.50 )
Ranked among companies with meaningful Days Payable only.
ENZY' s Days Payable Range Over the Past 10 Years
Min: 72.95  Med: 116.08 Max: 175.92
Current: 135.5
72.95
175.92

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.44
ENZY's Price/Net Cash is ranked higher than
54% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. ENZY: 5.44 )
Ranked among companies with meaningful Price/Net Cash only.
ENZY' s Price/Net Cash Range Over the Past 10 Years
Min: 5.38  Med: 6.84 Max: 10.39
Current: 5.44
5.38
10.39
Price/Net Current Asset Value 2.43
ENZY's Price/Net Current Asset Value is ranked higher than
81% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. ENZY: 2.43 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ENZY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.43  Med: 2.93 Max: 14.91
Current: 2.43
2.43
14.91
Price/Tangible Book 1.32
ENZY's Price/Tangible Book is ranked higher than
90% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. ENZY: 1.32 )
Ranked among companies with meaningful Price/Tangible Book only.
ENZY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.18  Med: 1.5 Max: 6.82
Current: 1.32
1.18
6.82
Price/Median PS Value 0.96
ENZY's Price/Median PS Value is ranked higher than
51% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ENZY: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
ENZY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 1.04 Max: 1.25
Current: 0.96
0.38
1.25
Price/Graham Number 1.55
ENZY's Price/Graham Number is ranked higher than
74% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 2.92 vs. ENZY: 1.55 )
Ranked among companies with meaningful Price/Graham Number only.
ENZY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.88  Med: 1.5 Max: 3.35
Current: 1.55
0.88
3.35
Earnings Yield (Greenblatt) (%) 3.70
ENZY's Earnings Yield (Greenblatt) (%) is ranked higher than
86% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. ENZY: 3.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENZY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 4.3 Max: 13.9
Current: 3.7
1.9
13.9

More Statistics

Revenue (TTM) (Mil) $51.40
EPS (TTM) $ 0.19
Short Percentage of Float0.28%
52-Week Range $6.60 - 10.70
Shares Outstanding (Mil)22.72

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 56 65
EPS ($) 0.25 0.50
EPS w/o NRI ($) 0.25 0.50
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ENZY

Headlines

Articles On GuruFocus.com
Julian Robertson Cuts Half of Stake in Paulson-Backed Company Jul 01 2016 
Tiger Management Founder Julian Robertson Ups Stake in Enzymotec Dec 07 2015 
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

More From Other Websites
Edited Transcript of ENZY earnings conference call or presentation 9-Aug-16 12:30pm GMT Aug 19 2016
Should You Get Rid of Enzymotec (ENZY) Now? Aug 18 2016
Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 Aug 15 2016
Enzymotec misses 2Q profit forecasts Aug 09 2016
Enzymotec misses 2Q profit forecasts Aug 09 2016
Enzymotec Ltd. Reports Second Quarter 2016 Unaudited Financial Results Aug 09 2016
Q2 2016 Enzymotec Ltd Earnings Release - Before Market Open Aug 09 2016
Enzymotec Ltd. To Present at Two Upcoming Investor Conferences Aug 02 2016
Enzymotec Ltd. To Present at Two Upcoming Investor Conferences Aug 02 2016
Enzymotec to Report Second Quarter 2016 Financial Results Jul 26 2016
Enzymotec to Report Second Quarter 2016 Financial Results Jul 26 2016
2016-07-18 Enzymatica AB: Excellent volume growth for ColdZyme® Jul 18 2016
CORRECTING and REPLACING -- Enzymotec Ltd. Calls its 2016 Annual General Meeting of Shareholders Jul 13 2016
CORRECTING and REPLACING -- Enzymotec Ltd. Calls its 2016 Annual General Meeting of Shareholders Jul 13 2016
Enzymotec Ltd. Calls for its 2016 Annual General Meeting of Shareholders Jul 13 2016
Julian Robertson Sells Half of Stake in John Paulson-Backed Company Jul 01 2016
Enzymotec (ENZY): Julian Robertson’s Tiger Management Dumps Half of Its Stake Jul 01 2016
2016-05-25 Bulletin from the Annual General Meeting in Enzymatica AB (publ) May 25 2016
Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 May 23 2016
Edited Transcript of ENZY earnings conference call or presentation 19-May-16 12:30pm GMT May 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)